Medical device biological testing evaluates the biocompatibility and safety of devices and materials that contact human tissue, blood, or mucosal membranes, in accordance with the ISO 10993 standard series and regional requirements such as GB/T 16886. This technical guide explains the biological evaluation framework, sample categories, core test items, laboratory methods, and regulatory applications that manufacturers must understand to bring safe medical devices to global markets.
Technical Overview
Medical device biological testing, also known as biocompatibility testing or biological evaluation, is the systematic assessment of the interactions between medical device materials and living tissue. The purpose is to determine whether a device or its constituent materials produce unacceptable biological risks, including cytotoxicity, irritation, sensitization, systemic toxicity, genotoxicity, and blood damage. The internationally recognized framework is defined by the ISO 10993 series of standards, which is harmonized in China as the GB/T 16886 series and widely referenced by regulatory authorities worldwide.
According to ISO 10993-1, biological evaluation must be conducted within a risk management process (aligned with ISO 14971) rather than as a simple checklist of laboratory tests. The evaluation begins with material characterization and chemical analysis of extractables and leachables, followed by a rationale-based selection of biological endpoint tests. Devices are first categorized by the nature of body contact and the duration of contact:
- Surface-contacting devices: contact with intact skin, mucosal membranes, or breached surfaces
- External communicating devices: contact with tissue, bone, dentin, or blood at indirect or direct paths into the body
- Implantable devices: contact with tissue or blood for extended periods inside the body
- Contact duration categories: limited exposure (up to 24 hours), prolonged exposure (24 hours to 30 days), and permanent contact (more than 30 days)
Testing is typically performed by accredited third-party laboratories operating under ISO/IEC 17025 quality systems or Good Laboratory Practice (GLP) principles, ensuring that study data is accepted by regulators across jurisdictions.
Testing Samples
Surface-Contacting Devices
Devices that contact intact or damaged skin or mucous membranes, such as wound dressings, surgical drapes, adhesive tapes, electrode gels, catheter fixation devices, contraceptive devices, and respiratory masks. These products generally require a reduced set of endpoints, typically cytotoxicity, sensitization, and irritation or intracutaneous reactivity.
External Communicating Devices
Devices that enter the body through natural or surgical pathways, including infusion sets, syringes, blood collection tubes, dialyzers, endoscopes, laparoscopic instruments, tracheal tubes, and urinary catheters. Depending on contact site and duration, testing may extend to acute systemic toxicity, subchronic toxicity, genotoxicity, and hemocompatibility for indirect blood contact.
Implantable Devices
Devices placed surgically or otherwise inside the body for prolonged or permanent durations, such as orthopedic implants, bone screws, plates, cardiac stents, pacemakers, hernia meshes, dental implants, and absorbable sutures. These devices require the most comprehensive evaluation, including implantation testing, subacute and subchronic toxicity, genotoxicity, and in some cases carcinogenicity and degradation studies.
Materials, Components, and Extracts
In addition to finished devices, biological testing covers raw materials such as polymers, resins, metals, ceramics, adhesives, coatings, colorants, sterilization residuals, and primary packaging materials. Test samples are prepared as aqueous and non-aqueous extracts under standardized conditions defined in ISO 10993-12, using polar media such as saline or culture medium and non-polar media such as sesame oil, with extraction parameters such as 37 °C for 72 hours, 50 °C for 72 hours, or 70 °C for 24 hours depending on the material and clinical use conditions.
Testing Items
Core biological endpoints and their governing standards include the following:
- Cytotoxicity (ISO 10993-5): assessment of cell death, inhibition of cell growth, and morphological changes in mammalian cell cultures
- Sensitization (ISO 10993-10): evaluation of the potential to cause delayed-type hypersensitivity reactions
- Irritation and intracutaneous reactivity (ISO 10993-23): determination of localized inflammatory responses in skin, eye, or mucosa
- Acute, subacute, and subchronic systemic toxicity (ISO 10993-11): detection of harmful effects after single or repeated exposure
- Genotoxicity (ISO 10993-3): bacterial reverse mutation (Ames) test, chromosomal aberration test, and mouse lymphoma gene mutation assay
- Implantation testing (ISO 10993-6): local tissue response to materials implanted in muscle, bone, or subcutaneous tissue
- Hemocompatibility (ISO 10993-4): hemolysis, thrombosis, coagulation, platelet function, complement activation, and hematology endpoints
- Carcinogenicity and reproductive toxicity (ISO 10993-3): long-term studies required only when justified by risk assessment
- Ethylene oxide residuals (ISO 10993-7): quantification of EO and ethylene chlorohydrin after gas sterilization
- Material characterization and toxicological risk assessment (ISO 10993-17, ISO 10993-18): chemical identification and safety evaluation of extractables, leachables, and degradation products
Testing Methods
Biological testing combines in vitro laboratory methods, in vivo animal studies, and analytical chemistry. Test selection and methodology follow the matrices provided in ISO 10993-1 and the specific part standards, and sample preparation always follows ISO 10993-12.
- In vitro cytotoxicity: extract (elution) method, direct contact method, and indirect contact (agar diffusion) method, quantified via qualitative morphology scoring or quantitative viability assays such as MTT reduction
- Sensitization: guinea pig maximization test, Buehler test, and the non-animal murine local lymph node assay (LLNA)
- Irritation: intracutaneous reactivity in rabbits using device extracts, plus reconstructed human epidermis and ocular models as emerging alternatives
- Hemocompatibility: direct and indirect hemolysis testing (commonly referenced with ASTM F756), thromboresistance evaluation, and complement activation assays
- Chemical characterization: gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), inductively coupled plasma mass spectrometry (ICP-MS), high-performance liquid chromatography (HPLC), and Fourier-transform infrared spectroscopy (FTIR) for extractables and leachables profiling
- Implantation studies: macroscopic and histopathological examination of tissue surrounding implanted test and control materials at defined time points
Modern practice emphasizes the 3Rs principle (replacement, reduction, and refinement of animal use), encouraging chemical characterization combined with toxicological risk assessment and validated in vitro alternatives wherever scientifically justified.
Applications
Biological test reports are essential deliverables across the entire product lifecycle and support the following regulatory and quality activities:
- Market authorization submissions, including premarket notifications and approvals in the United States, CE marking technical documentation under the EU Medical Device Regulation (MDR), and registration dossiers with the NMPA in China
- Qualification of new materials, alternate suppliers, and material formulations during design and development
- Impact assessment for design changes, manufacturing process changes, and sterilization method changes
- Support for sterilization validation, including ethylene oxide residual release testing
- Risk management documentation and post-market surveillance in accordance with ISO 14971
- Product stewardship for IVD consumables, surgical instruments, wound care products, and combination products
FAQ
What is the difference between biological evaluation and biological testing?
Biological evaluation is the overall risk-based process defined by ISO 10993-1, encompassing material characterization, existing data review, and gap analysis. Biological testing refers to the specific laboratory studies performed only when adequate existing data is unavailable. A documented biological evaluation plan and report are required to justify the final testing strategy.
How do I know which tests my device requires?
Test selection is based on the body contact category, contact duration, and material composition. A blood-contacting permanent implant requires far more endpoints than a skin-contacting disposable device. Manufacturers should prepare a matrix comparison against ISO 10993-1 and consult accredited third-party laboratories or regulatory experts to confirm the final scope.
How many samples are required for testing?
Sample quantity depends on the device surface area, extraction ratio, number of test endpoints, and required replicates. Generally, sufficient devices must be provided to deliver the standardized extraction area per ISO 10993-12, and sterile devices should be submitted in their final sterilized, packaged condition.
How long does biological testing take?
In vitro cytotoxicity can be completed within two to four weeks, while sensitization and implantation studies may require eight weeks to several months depending on the observation period. Genotoxicity and chemical characterization timelines depend on method complexity and analytical follow-up.
Are ISO 10993 results accepted globally?
The ISO 10993 series is recognized in most major jurisdictions, and the GB/T 16886 series is technically aligned with it. However, regulators may impose additional requirements, such as specific in vivo study preferences or Chinese pharmacopoeia methods, so regional strategy should be confirmed early in development.